Autoimmune Diseases

A new Chinese study highlights a potential cell therapy strategy for autoimmune diseases in a clinic setting.

A new study theorizes organs affected by autoimmune disease suppress immune cells using methods similar to those used by cancer cells to evade detection.

Results of 20-year cohort study reveal that women with history of this serious medical illness are more vulnerable to lupus.

New research has revealed that this approach could aid in the treatment of autoimmune diseases, as well as help with diabetes, chronic pain and numerous other conditions.

A new Swedish study examined gender differences in rheumatism and other autoimmune diseases. Here are the surprising findings.

A new study has surprising findings about traumatic or stressful life events and the link to developing an autoimmune disease.

A South Korean study may contribute to the improvement of personalized therapeutic outcomes for rheumatoid arthritis by expanding the scope of molecular imaging.

A new study on the overlap between the causes of rheumatoid arthritis and Huntington’s disease opens up new therapeutic targets and drugs for both conditions.

A neurologist and autoimmune expert at UT Southwestern shares insight into using large biobanks to understand and treat this rare autoimmune disease.

A Canadian study considers whether concerns over a link between the HPV vaccine and autoimmune disorders have merit.

A Canadian study has exciting findings about offspring exposed to tumor necrosis factors.

Experts weigh in on the spending outlook for these high-cost conditions.

More targeted therapies for autoimmune diseases are on the horizon. Here’s what to anticipate in 2018.

For the fourth consecutive year, diabetes therapy topped the list of contributors to drug use trends in therapeutic categories, contributing 16.1% to overall growth in drug spending in 2010 due to an increasing number of patients, according to the recently released 2011 Medco Drug Trend Report, which tracks utilization and spending.

Patients with inflammatory rheumatic disease may need 2 doses of adjuvanted split influenza A vaccine to elicit the same antibody response as healthy individuals, reported a recent Swiss study published in Arthritis & Rheumatism.

An analysis of data from more than 90,000 Medicare managed care enrollees who received care for rheumatoid arthritis found that more than one-third did not receive the recommended treatment with a disease-modifying antirheumatic drug, and that receipt varied by demographic factors, socioeconomic status, geographic location, and health plan, according to a study in JAMA.

Patients with rheumatoid arthritis who are seen by a rheumatologist within 12 weeks of symptom onset were likely to experience less joint destruction and have a higher chance of achieving disease modifying anti-rheumatic drug-free remission, according to a new study published December 2010 in Arthritis & Rheumatism.

Researchers from the Cincinnati Children's Hospital Medical Center have demonstrated that the tumor necrosis factor-alpha inhibitor etanercept is associated with significant increases in height, weight, and body mass index in children with juvenile idiopathic arthritis, according to a study recently published in Arthritis & Rheumatism.

A newly approved drug, denosumab (Xgeva, Amgen), delays skeletal-related side effects for 5 months longer compared to zoledronic acid (Zometa and Reclast, Novartis) in patients with breast cancer and bone metastases, according to phase 3 trial results presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, Texas.

New indication: Zoledronic acid (Reclast), a bisphosphonate, was approved on May 29, 2009, for the prevention of osteoporosis in postmenopausal women

Centocor Ortho Biotech has issued a Dear Healthcare Professionals letter to remind healthcare providers that golimumab (Simponi), a tumor necrosis factor (TNF)-alpha blocker, is associated with a risk of serious fungal infections.

Osteoarthritis (OA) is the most common form of arthritis and the leading cause of disability in the United States, especially among older adults. This article reviews nonpharmacologic and pharmacologic approaches to management of OA of the knee and hip.

In a study published in the Journal of the American Medical Association, investigators demonstrated an association between treatment with the anti-tumor necrosis factor (TNF)-alpha monoclonal antibodies (mAbs) adalimumab and infliximab and risk of herpes zoster events in patients with rheumatoid arthritis (RA).

In an analysis of fracture risk associated with loop diuretic use among postmenopausal women in the Women's Health Initiative (WHI) study, investigators demonstrated no significant association between loop diuretic use and fractures or changes in bone mineral density (BMD). With prolonged use of loop diuretics, however, the risk of fracture was modestly increased.